What is Sacral Neuromodulation for Overactive Bladder?
Overactive bladder (OAB) is a common and often distressing condition characterized by a sudden, compelling urge to urinate that is difficult to defer, often leading to involuntary loss of urine (urge incontinence), increased urinary frequency, and nocturia (waking up at night to urinate) [1]. This condition significantly impacts the quality of life for millions worldwide, with prevalence increasing with age [1]. While conservative therapies and oral medications are often the first line of treatment, a substantial number of individuals experience refractory OAB, meaning their symptoms do not adequately respond to these conventional approaches [1]. For these patients, sacral neuromodulation (SNM) has emerged as a valuable and effective therapeutic option.
Understanding Overactive Bladder
OAB is defined by the International Continence Society as urinary urgency, usually accompanied by frequency and nocturia, with or without urge incontinence, in the absence of urinary tract infection or other obvious pathology [2]. The underlying causes of OAB are complex and can involve abnormalities in the central nervous system, leading to an imbalance in bladder control [1]. It is generally understood to result from intermittent spasms of the pelvic floor musculature and/or bladder, or from issues such as phasic smooth muscle detrusor contractions, activation of sensory afferent nerves, enhanced excitatory transmission in the central nervous system (CNS), or reduced CNS central inhibition [1]. The economic burden of OAB is substantial, highlighting the need for effective treatment strategies [1].
The Role of Sacral Neuromodulation
Sacral neuromodulation is a minimally invasive surgical therapy designed to restore normal bladder function by modulating the neural pathways that control the bladder, bowel, and pelvic floor [1]. The concept of electrical stimulation for bladder control was first introduced in 1988 by Tanagho and Schmidt, involving the placement of an electrode implant in the S3–S4 sacral foramen to provide chronic electrical stimulation to the sacral nerves [12]. The US Food and Drug Administration (FDA) approved SNM for the treatment of urge urinary incontinence in 1997 and subsequently for urinary retention and frequency-urgency syndrome in 1999 [1].
Mechanism of Action
Despite its widespread use and proven efficacy, the precise mechanism of action of SNM is not yet fully understood [1]. However, several theories have been proposed. It is theorized that SNM moderates the normal micturition reflex by stimulating somatic afferent inhibition of sensory processing of the bladder within the spinal cord [1]. The most widely accepted hypothesis suggests that the effect stems from the stimulation of alpha myelinated afferent fibers and unmyelinated C fibers in the S3 and S4 pelvic and pudendal nerve roots, which influence the micturition reflex [1]. SNM uses electrical stimulation to essentially recalibrate the pacemaker for the bladder, which are the sacral nerves that innervate the musculature of the pelvic floor and lower urinary tract [1]. Another theory posits a direct inhibitory input to the bladder, suppressing bladder overactivity and decreasing pelvic floor spasticity [1].
Efficacy and Outcomes
Numerous studies have demonstrated the short-term and long-term efficacy of SNM for refractory OAB symptoms. For urge incontinence, studies have shown significant improvements, with many patients experiencing a 50% or greater reduction in symptoms. For instance, one study reported a decrease in incontinence episodes from a mean of 8.8 per day to 2.3 per day at 6-month follow-up, alongside a reduction in pad usage [20]. Long-term follow-up studies have corroborated these findings, with sustained improvements observed even after 5 years [21].
Regarding urgency and frequency, SNM has also shown considerable benefits. Patients often experience a significant reduction in daily voids and an increase in average voided volume. For example, a study reported a decrease from a mean of 17.7 voids per day to 10.6 voids per day after 2 years, with a corresponding increase in voided volume [11]. These improvements have been observed across various patient populations, including those with underlying neurological conditions, suggesting a broad applicability of SNM [24].
Complications and Safety
While SNM is an effective treatment, it is not without potential complications. Studies indicate a complication rate of approximately 30%–40% within the first 5 years, often necessitating surgical intervention such as device revision or removal [1]. Common adverse events include pain at the stimulator site, new pain, suspected lead migration, infection, and transient electric shock [1]. The timing of these complications can vary, with hematoma and infection typically occurring acutely post-surgery, while lead migration and modulator-related pain may manifest later [1]. Despite these risks, SNM is generally considered safe, and ongoing research aims to identify predictive factors for successful outcomes and minimize adverse events [1].
Cost-Effectiveness
The economic aspect of SNM is a significant consideration due to the initial high cost of the surgery and device implantation. However, studies have explored the long-term cost-effectiveness of SNM compared to other treatments for OAB, such as botulinum toxin A injections and continuous medical management. While initial costs for SNM may be higher, some analyses suggest that it can be more cost-effective in the medium to long term due to sustained benefits and reduced ongoing treatment expenses [33] [34]. For instance, one study found SNM to be cost-effective after 3 years and more cost-effective than botulinum toxin A at 10 years, considering both lower costs and higher efficacy [33]. These findings highlight the importance of considering the long-term economic impact when evaluating treatment options for refractory OAB.
Conclusion
Sacral neuromodulation represents a well-established and effective therapeutic option for individuals suffering from refractory overactive bladder symptoms. By modulating sacral nerves, SNM can significantly improve symptoms of urge incontinence, urinary frequency, and urgency, thereby enhancing patients' quality of life. While potential complications exist, the long-term benefits and favorable cost-effectiveness in many cases make SNM a valuable intervention for carefully selected patients. Continued research into its mechanisms, predictive factors, and long-term outcomes will further refine its application and optimize patient care.
References
[1] Sukhu, T., Kennelly, M. J., & Kurpad, R. (2016). Sacral neuromodulation in overactive bladder: a review and current perspectives. *Research and Reports in Urology*, *8*, 193–199. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/) [2] Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., ... & Wein, A. (2002). The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. *Neurourology and Urodynamics*, *21*(2), 167-178. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref2](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref2) [11] Siegel, S. W., Catanzaro, F., & Rupel, E. (2005). Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? *Urology*, *66*(4), 746-750. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref11](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref11) [12] Tanagho, E. A., & Schmidt, R. A. (1988). Electrical stimulation in the clinical management of the neurogenic bladder. *The Journal of Urology*, *140*(6), 1331-1339. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref12](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref12) [20] Latini, J. M., Alipour, M., & Kreder, K. J. (2006). Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. *Urology*, *67*(3), 550-553. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref20](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref20) [21] van Kerrebroeck, P. E., van Voskuilen, A. C., Heesakkers, J. P., ... & Koldewijn, E. L. (2007). Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. *The Journal of Urology*, *178*(5), 2029-2034. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref21](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref21) [24] Peters, K. M., Kandagatla, P., Killinger, K. A., Wolfert, C., & Boura, J. A. (2013). Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. *Urology*, *81*(4), 738-743. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref24](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref24) [33] Bertapelle, M. P., Vottero, M., Popolo, G. D., ... & Costantini, E. (2014). Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. *World Journal of Urology*, *33*(8), 1109-1117. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref33](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref33) [34] Arlandis, S., Castro, D., Errando, C., ... & Salinas, J. (2011). Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. *Value in Health*, *14*(2), 219-228. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref34](https://pmc.ncbi.nlm.nih.gov/articles/PMC5087764/#ref34)